<DOC>
	<DOCNO>NCT01876641</DOCNO>
	<brief_summary>The purpose study see combination Vemurafenib Decitabine plus Cobimetinib improve low therapy response rate subject malignant melanoma .</brief_summary>
	<brief_title>Treatment Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib</brief_title>
	<detailed_description>Primary Objectives Evaluate safety tolerability propose schedule decitabine Vemurafenib plus Cobimetinib treatment metastatic melanoma . Assess tumor response rate RECIST criterion Secondary Objectives To measure time progression patient treat combination comparison patient treat historically Vemurafenib alone ( current standard care BRAF-mutated patient )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : Male female &gt; /= 18 year old ECOG Performance Status &lt; /= 2 Meet follow lab criterion : Hematology Neutrophil count &gt; 1500/mm3 Platelet count &gt; 100,000/mm3 Hemoglobin &gt; /= 9 g/dL Biochemistry AST/ALT &lt; /= 2.5 x upper limit normal ( ULN ) &lt; /= 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin &lt; /= 1.5 x ULN Serum creatinine &lt; /=1.5 x ULN estimate creatinine clearance &gt; /= 50 ml/min CockcroftGault equation Total serum calcium ( correct serum albumin ) &gt; /= 8.5 mg/dL ionized calcium &gt; /= 3.8 mg/dL Serum potassium &gt; /= LLN Serum sodium &gt; /= LLN Serum albumin &gt; /= 3g/dl Baseline MUGA ECHO must demonstrate LVEF &gt; /= low limit institutional normal . TSH free T4 within normal limit , may thyroid hormone replacement Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first dose study drug . Willing use 2 method contraception , one barrier method study 3 month last study drug dose . Any patient metastatic melanoma ( site ) whose tumor V600EBRAF positive , regardless prior treatment . Prior treatment Vemurafenib allow Must take hypomethylating agent . Must disease progression follow recent treatment regimen presentation first time metastatic disease . Patients CNS disease eligible treatment CNS disease directly address radiation therapy . Exclusion criterion : Prior Decitabine treatment cancer Impaired cardiac function include one following : Screening ECG QTc &gt; 460 msec confirm central lab prior enrollment ; congenital long QT syndrome ; History sustain ventricular tachycardia ; History ventricular fibrillation/torsades de pointes ; Bradycardia define heart rate ( hr ) &lt; 50 beat per minute ; Patients pacemaker hr &gt; /= 50 beat per minute eligible ; Patients myocardial infarction unstable angina within 6 mo study entry ; CHF ( NYHA class III IV ) ; Right bundle branch block leave anterior hemiblock ; Uncontrolled hypertension Concomitant use drug risk cause torsades de pointes Concomitant use CYP3A4 , CYP1A2 , CYP2D6 substrates Unresolved diarrhea &gt; CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption Vemurafenib Other concurrent severe uncontrolled medical condition Patients receive prior therapy allow enroll washout period : Chemotherapy 3 week ( wk ) washout ; Oral agent 2 wk washout ( Except Vemurafenib , washout period ) ; Investigational agent 3 wk washout ; Immunotherapy 4 wk washout ; Palliative radiation therapy bone/brain 2 wk washout ; Major radiation surgical procedure 3 wk washout Concomitant use anticancer radiation therapy . No measurable disease Pregnant , breastfeed woman WOCBP willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( menses time precede 12 consecutive month ) . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom History another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin Known positivity HIV hepatitis C Any significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic melanoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>BRAF-mutated Metastatic Melanoma</keyword>
	<keyword>V600EBRAF-mutated metastatic melanoma</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Vemurafenib</keyword>
</DOC>